Prelude Therapeutics Announces Clinical Trial Collaboration with BeiGene to Evaluate PRT2527 in Combination with Zanubrutinib in Hematologic Cancers
15 mars 2023 08h00 HE
|
Prelude Therapeutics, Inc.
WILMINGTON, Del., March 15, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced a clinical trial...
Prelude Therapeutics To Participate in Barclays Global Healthcare Conference
01 mars 2023 08h30 HE
|
Prelude Therapeutics, Inc.
WILMINGTON, Del., March 01, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the company will...
Prelude Therapeutics To Participate in Two Upcoming Healthcare Investor Conferences
09 févr. 2023 09h05 HE
|
Prelude Therapeutics, Inc.
WILMINGTON, Del., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the company will...
Prelude Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business Update
14 nov. 2022 08h00 HE
|
Prelude Therapeutics, Inc.
FDA clearance of two new INDs: PRT3789 (First-in-class Selective SMARCA2 degrader) and PRT3645 (next generation CDK4/6 inhibitor) Company to reprioritize clinical pipeline and discontinue PRMT5...
Prelude Therapeutics Receives FDA Clearance of IND for PRT3789, a Potent and Selective First-in-Class SMARCA2 Protein Degrader
18 oct. 2022 08h00 HE
|
Prelude Therapeutics, Inc.
WILMINGTON, Del., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that the U.S. Food and...
Prelude Therapeutics To Participate in Upcoming HC Wainwright and Morgan Stanley Healthcare Conferences
06 sept. 2022 08h00 HE
|
Prelude Therapeutics, Inc.
WILMINGTON, Del., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the company will be...
Prelude Therapeutics Announces Second Quarter 2022 Financial Results and Business Update
09 août 2022 08h00 HE
|
Prelude Therapeutics, Inc.
Prelude Announces Acceptance of IND For a Differentiated and Brain Penetrant CDK4/6 inhibitor PRT3645 by the US Food and Drug Administration (FDA) Clinical data readouts and next steps for the PRMT5...
Prelude Therapeutics Announces First Quarter 2022 Financial Results and Operations Update
10 mai 2022 08h00 HE
|
Prelude Therapeutics, Inc.
Prelude remains on track for clinical data readouts and next steps for the PRMT5 program, MCL1 inhibitor PRT1419, and CDK9 inhibitor PRT2527 in 2H2022 Strong cash and cash equivalents of $266.2...
Prelude Therapeutics Reports Full Year 2021 Financial Results
16 mars 2022 07h30 HE
|
Prelude Therapeutics, Inc.
Significant progress achieved in 2021: Pipeline now includes six internally discovered small molecule compounds targeting clinically validated pathways in cancers with underserved patients Objectives...
Prelude Therapeutics to Participate at the Barclays 2022 Global Healthcare Conference
11 mars 2022 08h00 HE
|
Prelude Therapeutics, Inc.
WILMINGTON, Del., March 11, 2022 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that Kris Vaddi, PhD, Chief Executive...